Latent tuberculosis infection treatment for prison inmates: A randomised controlled trial

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 5, 2012, Pages 633-638

  Chan, P C ^a,b,c   Yang, C H ^a   Chang, L Y ^c   Wang, K F ^a   Lu, B Y ^a   Lu, C Y ^c   Shao, P L ^c   Hsueh, P R ^c   Fang, Chi Tai ^b,c   Huang, L M ^c  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hepatotoxicity; Isoniazid; Rifampicin

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; ISONIAZID; RIFAMPICIN; TUBERCULIN;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS C; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PRISON; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TAIWAN; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA RELEASE TESTS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRISONERS; RIFAMPIN; TAIWAN; TREATMENT OUTCOME; TUBERCULIN TEST; YOUNG ADULT;

EID: 84859710523     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0504     Document Type: Article

References (26)

1. Horsburgh C R Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-2067.
2. Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1970; 26: 28-106.
3. International Union Against Tuberculosis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564.
4. Blumberg H M, Leonard M K Jr, Jasmer R M. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293: 2776-2784. (Pubitemid 40973380)
5. Chee C B E, Teleman M D, Boudville I C, Do S E, Wang Y T. Treatment of latent TB infection for close contacts as a complementary TB control strategy in Singapore. Int J Tuberc Lung Dis 2004; 8: 226-231. (Pubitemid 38622931)
6. Chan P C, Huang L M, Suo J S. It is time to deal with latent tuberculosis infection in Taiwan. J Formos Med Assoc 2009; 108: 901-903.
7. Baussano I, Williams B G, Nunn P, et al. Tuberculosis incidence in prisons: a systematic review. PLoS Med 2010; 7: e1000381.
8. Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC. MMWR Recomm Rep 2006; 55 (RR-9): 1-44.
9. Spaulding A C, Weinbaum C M, Lau D T, et al. A framework for management of hepatitis C in prisons. Ann Intern Med 2006; 144: 762-769. (Pubitemid 46780636)
10. Jasmer R M, Saukkonen J J, Blumberg H M, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137: 640-647. (Pubitemid 35176096)
11. Lobato M N, Reves R R, Jasmer R M, et al.; 2RZ Study Group. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest 2005; 127: 1296-1303.
12. Hong Kong Chest Service/British Medical Research Council. A double-blind placebo controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
13. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149: 689-697.
14. Kernan W N, Viscoli C M, Makuch R W, Brass L M, Horwitz R I. Stratified randomization for clinical trials. J Clin Epidemiol 1999; 52: 19-26. (Pubitemid 29064270)
15. National Cancer Institute. Common terminology criteria for adverse events, version 2.0. Bethesda, MD, USA: NCI, 2003. http://ctep.cancer.gov/ protocolDevelopment/electronic. application/ctc.htm Accessed February 2012.
16. American Thoracic Society Hepatotoxicity of Anti-tuberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
17. Page K R, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166: 1863-1870.
18. Sadaphal P, Astemborski J, Graham N M, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 2001; 33: 1687-1691. (Pubitemid 33044534)
19. Crzemska D M, Coninx R, Reyes H. Guidelines for the control of tuberculosis in prisons. WHO/TB/98.250. Geneva: World Health Organization, 1998.
20. Fernández-Villar A, Sopeña B, Vázquez R, et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003; 36: 293-298. (Pubitemid 36169664)
21. Kunst H, Khan K S. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 2010; 14: 1374-1381.
22. Smith B M, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ 2011; 183: E173-E179.
23. Trajman A, Long R, Zylberberg D, et al. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis 2010; 14: 551-559.
24. White M C, Tulsky J P, Reilly P, McIntosh H W, Hoynes T M, Goldenson J. A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail. Int J Tuberc Lung Dis 1998; 2: 506-512. (Pubitemid 28326316)
25. Nolan C M, Roll L, Goldberg S V, Elarth A M. Directly observed isoniazid preventive therapy for released jail inmates. Am J Respir Crit Care Med 1997; 155: 583-586. (Pubitemid 27085805)
26. Ziakas P D, Karsaliakos P, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009; 49: 1883-1889.